Risankizumab

Risankizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Targetinterleukin 23A
Clinical data
Pronunciation/ˌrɪsənˈkɪzʊmæb/
RIS-ən-KIZ-uu-mab
Trade namesSkyrizi
Other namesBI-655066, ABBV-066, risankizumab-rzaa
AHFS/Drugs.comMonograph
MedlinePlusa619035
License data
Pregnancy
category
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6476H9992N1720O2016S44
Molar mass145611.84 g·mol−1

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease.[6][7] It is designed to target interleukin 23A (IL-23A).[6][7][9] It is given by subcutaneous injection.[6][7]

The most common side effects include upper respiratory infections (nose and throat infection).[7]

Risankizumab is approved for medical use in the European Union,[7] the United States,[6][10] Canada,[3] and Japan.[8][11]

  1. ^ "Risankizumab (Skyrizi) Use During Pregnancy". Drugs.com. 15 July 2019. Retrieved 23 September 2020.
  2. ^ "Skyrizi (Abbvie Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Retrieved 9 April 2023.
  3. ^ a b "Skyrizi Product information". Health Canada. 25 April 2012. Retrieved 29 May 2022.
  4. ^ "Summary Basis of Decision (SBD) for Skyrizi". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  5. ^ "Skyrizi 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). Retrieved 23 September 2020.
  6. ^ a b c d e "Skyrizi- risankizumab-rzaa kit". DailyMed. 12 June 2020. Retrieved 23 September 2020.
  7. ^ a b c d e f "Skyrizi EPAR". European Medicines Agency (EMA). 27 February 2019. Retrieved 23 September 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^ a b "AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis". AbbVie (Press release). 23 April 2019. Retrieved 9 August 2023.
  9. ^ Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. (July–August 2015). "Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody". mAbs. 7 (4): 778–791. doi:10.1080/19420862.2015.1032491. PMC 4622456. PMID 25905918.{{cite journal}}: CS1 maint: overridden setting (link)
  10. ^ Cite error: The named reference FDA approval package was invoked but never defined (see the help page).
  11. ^ "Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis". The Rheumatologist. 15 April 2019.